| __timestamp | Amneal Pharmaceuticals, Inc. | CRISPR Therapeutics AG |
|---|---|---|
| Wednesday, January 1, 2014 | 335989000 | 1513000 |
| Thursday, January 1, 2015 | 367054000 | 12573000 |
| Friday, January 1, 2016 | 420770000 | 42238000 |
| Sunday, January 1, 2017 | 507476000 | 69800000 |
| Monday, January 1, 2018 | 946588000 | 113773000 |
| Tuesday, January 1, 2019 | 1273376000 | 179362000 |
| Wednesday, January 1, 2020 | 1364130000 | 269407000 |
| Friday, January 1, 2021 | 1324696000 | 17953000 |
| Saturday, January 1, 2022 | 1427596000 | 110250000 |
| Sunday, January 1, 2023 | 1573042000 | 130250000 |
| Monday, January 1, 2024 | -2314000 |
Unlocking the unknown
In the ever-evolving landscape of biotechnology, understanding cost dynamics is crucial. Amneal Pharmaceuticals, Inc. and CRISPR Therapeutics AG, two titans in the industry, have shown contrasting trends in their cost of revenue from 2014 to 2023. Amneal Pharmaceuticals has seen a steady increase, with costs rising by approximately 370% over the decade, peaking at $1.57 billion in 2023. This growth reflects their expanding operations and market reach. In contrast, CRISPR Therapeutics AG, a pioneer in gene editing, has experienced more volatile cost patterns. Their costs surged by over 8,500% from 2014 to 2020, reaching a high of $269 million, before stabilizing. This fluctuation mirrors the innovative yet unpredictable nature of the gene-editing sector. As these companies continue to innovate, monitoring their cost structures will provide insights into their strategic directions and market adaptations.
Johnson & Johnson vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Gilead Sciences, Inc. vs Amneal Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Zoetis Inc. vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Comparison: GSK plc vs CRISPR Therapeutics AG
Dr. Reddy's Laboratories Limited vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Walgreens Boots Alliance, Inc. vs Amneal Pharmaceuticals, Inc.
Analyzing Cost of Revenue: Exelixis, Inc. and CRISPR Therapeutics AG
Cost of Revenue: Key Insights for Pharming Group N.V. and CRISPR Therapeutics AG
Analyzing Cost of Revenue: Cytokinetics, Incorporated and CRISPR Therapeutics AG
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
Cost of Revenue Trends: Amneal Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Cost of Revenue Comparison: Amneal Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.